Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Moricizine: a new class I antiarrhythmic.

H J Mann1

  • 1Department of Pharmacy Practice, College of Pharmacy, University of Minnesota, Minneapolis 55455.

Clinical Pharmacy
|November 1, 1990
PubMed
Summary

Moricizine hydrochloride, a Class I antiarrhythmic, effectively reduces ventricular arrhythmias and is better tolerated than some alternatives. Its use is limited to life-threatening arrhythmias due to potential proarrhythmic effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changes in vasopressin use and outcomes in surgical intensive care unit patients with septic shock.

Chirurgia (Bucharest, Romania : 1990)·2009
Same author

Pharmacokinetics of tiletamine and zolazepam (Telazol) in anesthetized pigs.

Journal of veterinary pharmacology and therapeutics·2006
Same author

Pharmacy technology of the ICU. Today and tomorrow.

Critical care clinics·2000
Same author

Effect of pharmacokinetic sampling methods on aminoglycoside dosing in critically ill surgery patients.

Pharmacotherapy·1998
Same author

Hollow fiber bioartificial liver utilizing collagen-entrapped porcine hepatocyte spheroids.

Biotechnology and bioengineering·1996
Same author

Extrahepatic metabolism of 4-methylumbelliferone and lidocaine in the anhepatic rabbit.

Drug metabolism and disposition: the biological fate of chemicals·1996

Area of Science:

  • Cardiology
  • Clinical Pharmacology

Background:

  • Moricizine hydrochloride is a Class I antiarrhythmic agent.
  • It exhibits electrophysiologic actions including decreased depolarization rate and altered repolarization.
  • Its clinical profile is compared to other antiarrhythmic drugs.

Purpose of the Study:

  • To review the chemistry, pharmacology, pharmacokinetics, clinical efficacy, adverse effects, and dosage of moricizine hydrochloride.
  • To evaluate its role in treating life-threatening cardiac arrhythmias.

Main Methods:

  • Review of existing literature on moricizine hydrochloride.
  • Analysis of electrophysiologic effects, clinical trial data, and adverse event profiles.

Main Results:

  • Moricizine reduces ventricular premature contractions and various forms of ventricular tachycardia.
  • It demonstrates efficacy comparable to quinidine but less than flecainide or encainide.
  • It is generally better tolerated with less proarrhythmic potential than some other agents.

Conclusions:

  • Moricizine hydrochloride is effective for documented life-threatening arrhythmias.
  • Its indications are limited due to proarrhythmic risk.
  • It presents a therapeutic option competing with other first-line antiarrhythmic agents.

Related Experiment Videos